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Pancreatic ductal adenocarcinoma is characterised by poor oncological outcomes with curative treat-
ment only possible for a minority. Symptoms are dependent on the stage of the disease and location
within the pancreas with constitutional decline often prominent. Patients require biochemical in-
vestigations and accurate imaging with CT to determine stage of disease and local resectability. CT-PET
and endoscopic ultrasound are increasingly used preoperatively. Surgery remains the cornerstone of
curative management and can be performed using minimally invasive approaches. Vascular resection
and combination treatment with chemoradiotherapy are also utilised for suitable patients. Perioperative
outcomes may be optimised using enhanced recovery pathways. Quality standards have been defined for
individual clinicians and units to benchmark their clinical outcomes. The developments described hold
promise in improving outcomes from pancreatic ductal adenocarcinoma.
© 2019 Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal dis-
ease with annual mortality approaching the incidence.1 Potentially
curative treatment is possible only for a minority of patients, is
resource-intensive and requires multidisciplinary management but
provides the best option for improved outcomes. Although appre-
ciable gains in survival are yet to be seen, there have been a number
of recent advances in the management of PDAC. The aim of this
review is to provide an overview of contemporary management of
PDAC and expand upon newer trends and contentious areas per-
taining to investigation and treatment.
2. Diagnosis & staging
2.1. Clinical presentation
Symptoms from PDAC are dependent on the stage of disease
and location of the malignancy within the pancreas. Early stage
disease is often asymptomatic or characterised by non-specific
constitutional symptoms such as weight loss and anorexia.ry of Edinburgh; Department
h, UK.
d to Zhejiang University School of
y-nc-nd/4.0/).
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.org/10.1016/j.lers.2019.07.00Symptoms can include abdominal or back pain - the latter often
being a sign of coeliac plexus involvement and potential unre-
sectability - and jaundice if malignancy in the head of pancreas
causes biliary obstruction.2 Painless jaundice remains a common
mode of presentation. The lack of overt symptoms frommalignancy
in the body and tail often results in advanced malignancy by the
time of diagnosis. Clinical signs of pancreatic malignancy may
include jaundice, nutritional sequalae or abdominal findings such
as a palpable gallbladder, ascites or presence of a Sister Mary Joseph
nodule.
With the increasing recognition of pre-cancerous conditions
such as intraductal papillary mucinous neoplasms (IPMN) and the
widespread use of imaging, incidental diagnosis is becoming a
commoner mode of presentation with the diagnosis made on the
basis of imaging rather than clinical presentation.32.2. Laboratory investigations
Any patient suspected of having a pancreatic malignancy
should have basic blood tests including full blood count, electro-
lytes, liver function tests and clotting function. These provide
valuable information regarding the patient's current state and any
acute issues that may need to be addressed, such as jaundice or
anaemia. They also provide some indication of the patient'sMedicine. Published by Elsevier B.V. This is an open access article under the CC BY-
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also provide useful baseline information and help clarify diag-
nostic uncertainty, such as between adenocarcinoma and neuro-
endocrine tumours. There is increasing information that the CA
19-9 trend may be indicative of response to chemotherapy (see
below) but it is important to note that since CA 19-9 is a blood
group antigen, a percentage of any population (e.g. up to 35% of
the black population) may not secrete it.4,5Fig. 2 Mass in head of pancreas involving SMV/PV.
CT showing an uncinate mass with abutment of PV (Borderline resectable). The patient
underwent pancreaticoduodenectomy with en bloc PV resection and reconstruction.2.3. Imaging
Although some patients will have an abdominal ultrasound as
part of an initial evaluation of abdominal pain and jaundice, or due
to clinical suspicion of gallstones, the diagnosis of probable PDAC is
usually made by dedicated abdominal CT.6,7 CT serves multiple
purposes and remains the cornerstone of diagnosis, staging and
pre-operative planning.6 Multiphase, multidetector helical CT with
three-dimensional reconstruction is the current gold-standard.6
PDAC has abundant fibrous stroma and hypovascularity and thus
enhances poorly compared to normal pancreatic parenchyma.8 CT
can evaluate the interface between a head of pancreas mass and its
relationship to the superior mesenteric vein/portal vein (SMV/PV),
superior mesenteric artery (SMA) and other vasculature (e.g. he-
patic artery) as seen in Figs. 1 and 2.1 Similarly, body/tail masses can
be evaluated for their relationship to the coeliac trunk and left
adrenal gland. Involvement of local structures represents relative/
absolute contraindications to resection and can also provide valu-
able information for planning an extended resection when appro-
priate. Moreover, CT can identify clinically important anatomical
variants such as a replaced right hepatic artery or coeliac artery
stenosis which can impact on subsequent surgical intervention.
CT can also help determine if distant metastases (e.g. liver/lung)
or lymph nodes outside the field of resection are present, and thus
stage the patient accurately. A meta-analysis by Bipat et al reported
sensitivity and specificity rates for helical CT in tumour detection of
91% and 85% respectively, with slightly lower values of 81% and 82%
for determining resectability.7 However, CT is not ideal for detect-
ing small peritoneal nodules or lymph node metastases in normal-
sized nodes.8 In addition, its diagnostic accuracy in the preopera-
tive assessment of extraregional lymph node metastases is low due
to poor sensitivity.9Fig. 1 Mass in head of pancreas with preserved PV/SMV fat-plane.
CT showing an ampullary mass with a clear fat plane around the SMV. This patient
underwent routine pancreaticoduodenectomy.
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be used to assess the pancreatic parenchyma and pancreatic duct
when evaluating patients with IPMN.8,10 Dedicated liver MRI can be
used to evaluate indeterminate liver lesions to exclude metasta-
ses.11 Some institutions also employ either selective or routine
staging laparoscopy to diagnose occult peritoneal disease or me-
tastases not visible on imaging.12,13 The diagnostic yield of this is
increasingly small due to constant improvements in imaging
technology and the cumulative accuracy of multiple investigations
of varying modalities in an individual patient.12,14 However, diag-
nostic laparoscopy has been shown to decrease the rate of futile
laparotomies and is still employed in some institutions.13,15
In a recent study, fluorodeoxyglucose-positron emission to-
mography CT (FDG-PET CT) (see Fig. 3) was shown to provide more
accurate staging information preoperatively and changed decision
making in 45% of patients.16 It has been shown to be cost effective
by reducing the number of patients undergoing potentially
unnecessary surgery and was shown to detect CT-occult metastases
in an extra 20% of patients who had otherwise been fullyFig. 3 PET-avid mass in head of pancreas.
FDG-PET CT showing avid head of pancreas mass.
e management of pancreatic ductal adenocarcinoma, Laparoscopic,
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selection and may decrease the number of patients who may have
early distant recurrence due to undiagnosed occult metastases. In
the United Kingdom, the routine use of FDG-PET CT has now been
recommended for all patients with PDAC being considered for
treatment with curative intent in recently published guidelines.17
FDG-PET CT has also been described as providing a dynamic indi-
cator of response to chemotherapy in patients undergoing neo-
adjuvant treatment and can be a proxy of complete pathological
response if previously metabolically active disease is not visible on
repeat imaging after treatment.4 It is important to note, however,
that the diagnostic accuracy of FDG-PET CT suffers in patients with
diabetes, and obtaining an extra investigation may possibly cause
delays in providing definitive treatment.18,19
2.4. Endoscopic ultrasound
Historically, the diagnosis of PDAC was made radiologically and
suitable patients were recommended for surgery without a tissue
diagnosis.20 A false-positive rate due to benign mass-forming
chronic pancreatitis was previously accepted despite the rela-
tively high morbidity and mortality associated with surgery.20 This
was due to the difficulties in obtaining tissue with the retroperi-
toneal location of the pancreas and concerns of inadvertent organ/
vascular injury and seeding malignancy. However, endoscopic ul-
trasound (EUS) has overcome these problems and is now
commonly employed to visualise pancreatic masses. It is particu-
larly useful for head of pancreas lesions as it can provide comple-
mentary information to CT by assessing the relationship of themass
to the SMV/PV or SMA.21 Moreover, EUS can be used to get either
cytological or histological information using fine needle aspirate or
core biopsies to obtain a definitive diagnosis before proceeding to
surgery.22 It can also be used to sample suspicious lymph nodes
which may be out of the resection field and therefore help deter-
mine resectability.22 As the use of neoadjuvant chemotherapy be-
comes increasingly common, preoperative diagnosis of cancer
using EUS is crucial and an attempt at obtaining a tissue diagnosis
prior to considering major pancreatic resection in all patients
would seem prudent.17
3. Treatment options
Depending on the mode of diagnosis and patient symptoms, the
initial management of patients with PDAC can involve treatment of
sepsis, amelioration of jaundice and/or appropriate palliation.
Palliative management includes optimisation of nutrition and the
use of pancreatic enzyme supplements, treatment of symptoms
(e.g. pain, jaundice) as well as consideration of systemic chemo-
therapy.23 Since jaundice is usually caused by distal biliary
obstruction, endoscopic retrograde cholangiopancreatography
(ERCP) is the preferred modality to relieve jaundice whilst also
attempting tissue diagnosis with brushings.17 Since preoperative
biliary drainage (either with ERCP or with percutaneous biliary
dilatation) has been associated with an increased incidence of post-
operative complications, patients with jaundice without sepsis,
major electrolyte derangement or renal impairment, who are
otherwise good operative candidates and have resectable disease,
are excellent candidates for unstented pancreaticoduodenectomy
(PD).17,24 This requires considerable logistical capabilities within an
institution and canmean that obtaining all investigations (e.g. FDG-
PET CT and EUS-guided biopsy) in a short time-frame may be
challenging.17 Moreover, it may only allow minimal time for the
patient to comprehend the magnitude of the treatment proposed
but has been shown to provide superior postoperative
outcomes.24,25Please cite this article as: Srinivasa S, Parks R, Emerging concepts in th
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A minority of patients are suitable for treatment with curative
intent.1 The majority of patients are not suitable due to advanced
age and significant comorbidity which may be a contra-indication
for major pancreatic resection, or because the disease has either
metastasised or is locally unresectable.1 For suitable patients, the
surgical options are generally PD or distal/subtotal pancreatectomy.
A small number of patients require total pancreatectomy or central
pancreatectomy. Most patients are offered post-operative chemo-
therapy depending on final histology and post-operative progress.1
Surgery is associated with a morbidity rate of up to 50%, a 20% risk
of major complications and 5% risk of 90-day mortality.26 For true
head of pancreas adenocarcinoma - as compared to distal chol-
angiocarcinoma or duodenal carcinoma - the risk of a microscopi-
cally positive margin in patients deemed to be resectable remains
high.27
There have been a number of exciting developments in surgical
management. Minimally invasive pancreatic resections - either
laparoscopic or robotic - have begun to be implemented world-
wide. Laparoscopic distal pancreatectomy has been shown to be
associated with improved short term outcomes, decreased blood
loss and decreased complications.28e30 It has also been shown to
be cost effective and provides non-inferior oncological out-
comes.28e30 Laparoscopic PD has been reported by multiple cen-
tres worldwide.31e34 There is a steep learning curve but in expert
centres, has been reported to be associated with improved short
term outcomes with comparable long term results.31e34 Advo-
cates of laparoscopic PD recommend careful case selection and
acknowledge the potential difficulties of completing the operation
laparoscopically with one intermediate option being to consider
hybrid (laparoscopic dissection; open reconstruction) or hand-
assisted approaches.32,35e37 The only multi-centre trial
comparing laparoscopic to open PD was terminated early due to a
higher number of deaths in the laparoscopic arm.38 Another
alternative has been to employ a robotic approach which can
provide multiple hands and greater degrees of freedom compared
to the relatively restricted laparoscopic working angles.39,40
Published evidence on robotic pancreatic surgery suggests that
equivalent outcomes to laparoscopic surgery can be obtained but
with a less difficult learning curve, which is manifest in a
decreased rate of conversion to an open procedure.41 At present,
minimally invasive PD should be considered to be in the evalua-
tion stage and should be performed within a closely monitored
system to avoid undue harm, whilst laparoscopic distal pancrea-
tectomy can be considered to be best practice depending on sur-
geon and patient factors.
Open pancreatic resections have also seen some changes pro-
posed. The “artery-first” approach - early control and dissection of
the SMA to prove resectability - has been shown to improve the
likelihood of obtaining a negative resection margin.42 Although it is
unlikely to improve outcomes in all patients requiring PD, it is a
prudent approach for cancers affecting the uncinate process. Distal/
subtotal pancreatectomy has also seen the evolution of anterior and
posterior radical anterograde modular pancreaticosplenectomy
(RAMPS).42,43 This operation fundamentally assesses whether
pancreatic lesions are exophytic and compromise the pancreatic
capsule. The procedure involves early vascular control with medial
to lateral dissection and a wider margin. Posterior RAMPS encom-
passes the left adrenal gland and skeletonises Gerota's fascia en bloc
whereas anterior RAMPS goes behind the anterior renal fascia. The
technique is considered analogous to a total mesorectal excision for
rectal cancer and aims to increase the likelihood of a negative
tangential margin and an increased lymph node count.44 Initial
results from the pioneering centre and a subsequent systematice management of pancreatic ductal adenocarcinoma, Laparoscopic,
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negative margins and decreased local recurrence.44e46
3.2. Vascular resection
Poor oncological outcomes from PDAC following surgery relate
to both local and distant recurrence. To overcome the problem of
local recurrence, some centres have advocated the use of vascular
resection to minimise the risk of a positive margin.47 Whilst the
role of venous resection is well-established and thought to be a
useful strategy, albeit with a higher rate of perioperative morbidity,
some centres practice arterial resection and reconstruction.4,47,48
Results published from high-volume centres have reported a not
insignificant mortality rate but with impressive margin-negative
resection rates and overall survival.4,48 Although this has mainly
been reported in the context of PD, some centres have reported
coeliac trunk resection for body of pancreas malignancy.49 The
hepatic arterial inflow is then dependent on retrograde flow from
the gastroduodenal artery or is supplemented with formal recon-
struction or a jump graft. Others have advocated skeletonising
major vessels to obtain negative margins though in the case of the
SMA, this has been shown to cause debilitating diarrhoea.50
3.3. Neoadjuvant chemoradiotherapy
The use of neoadjuvant chemoradiotherapy represents a major
paradigm shift in the management of PDAC. Traditional manage-
ment has consisted of surgery for resectable patients followed by
adjuvant chemotherapy if appropriate.51 However, the definition of
resectability is increasingly viewed as a spectrum which includes
borderline resectable and locally advanced disease, as determined
by preoperative imaging.52,53 A number of studies have reported
trialling combination chemotherapy and radiotherapy for patients
with borderline resectable or locally advanced disease in an
attempt to downstage the disease before attempting trial dis-
section.4,54e56 The rationale for this strategy is akin tomanagement
of other solid organ neoplasms such as stomach and rectal cancer. It
allows patients to receive chemotherapy upfront, rather than being
unable to receive it postoperatively due to complications or a
protracted recovery.56,57 Moreover, it may prevent futile surgery in
patients who progress whilst receiving chemotherapy thus mani-
festing more aggressive tumour biology.56,57 Chemotherapy may
also decrease occult systemic tumour burden and decrease the rate
of metastatic recurrence.57 The role of radiotherapy is thought to
sterilise the difficult operative margins (SMA, retroperitoneum)
and decrease the risk of local recurrence.54 Conversely, since PDAC
is inherently chemoresistant, there is a risk that a period of ulti-
mately ineffectual chemotherapy may lead to patients missing a
vital therapeutic window and radiotherapy may increase the
perioperative morbidity due to deleterious effects on anastomotic
healing.58,59 Nonetheless, a number of centres have reported very
impressive survival with a high margin-negative resection rate and
acceptable perioperative morbidity when evaluating neoadjuvant
chemoradiotherapy followed by trial dissection.4,54,55 Intriguingly,
these studies suggest that radiological assessment of pancreatic
lesions may not be valid after neoadjuvant treatment as imaging is
unable to differentiate between persistent cancer and treatment-
induced fibrosis.4,54 Trial dissection in all patients without meta-
static disease is advocated. A potential role for FDG-PET CT and
monitoring with CA 19-9 measurements has been suggested in this
context.4
With the encouraging results reported by some centres for
borderline resectable and locally advanced disease, the next ques-
tion to be addressed is whether patients with resectable cancer
at presentation should also be treated with neoadjuvantPlease cite this article as: Srinivasa S, Parks R, Emerging concepts in th
Endoscopic and Robotic Surgery, https://doi.org/10.1016/j.lers.2019.07.00chemoradiotherapy.60 Despite the concerns of missing therapeutic
windows, the drop-off in patients proceeding to surgery due to
adverse effects and the physical toll of neoadjuvant treatment
regimens, recent evidence suggests that neoadjuvant chemo-
radiotherapy followed by surgery may offer superior survival
compared to surgery followed by chemotherapy.60,61 These results
are affected by case-mix, perioperative outcomes as well as the
choice of treatment regimens, but this remains an area in flux and
likely to see major changes in treatment pathways.
4. Perioperative care
Modern advances in perioperative care have challenged long-
standing surgical dogma such as enforced starvation and bed rest.
Enhanced recovery protocols are an important component of
providing benchmarked surgical care. This has been evaluated in
detail for patients undergoing pancreatic resection with recom-
mendations made for many aspects of perioperative care.62 These
include an emphasis on preoperative counselling and nutritional
optimisation as well as avoidance of prolonged fasting. The authors
recommend regional anaesthesia wherever possible and mainte-
nance of neutral fluid balance perioperatively. Routine use of
nasogastric tubes is discouraged with early feeding and mobi-
lisation recommended.
Two areas of ongoing discussion in perioperative management
include the use of perianastomotic drains and somatostatin ana-
logues. Whilst some surgeons advocate complete avoidance of
drains, the published literature is confounded by multiple differ-
ences such as the characteristics of the pancreas gland (e.g soft
versus firm) and whether the pancreatic duct is dilated.63,64
Moreover, whilst some studies have shown equivalent outcomes
in patients who have not had a drain placed, one multicentre trial
was terminated prematurely due to a higher rate of mortality in the
no-drain group.65 As such, most centres appear to favour the
default use of drains with exclusion in selected cases. The timing of
drain removal has also been studied with recommendations to-
wards early removal (24e72 hours) based on drain amylase
levels.66,67
Somatostatin analogues reduce pancreatic secretions and have
thus been investigated for their ability to decrease post-operative
pancreatic fistula (POPF). The evidence is, however, conflicting.
One single-centre randomised trial showed that pasireotide
decreased the rate of POPF but these results have not been repli-
cated in other settings.68e70 In a retrospective review of factors
predicting POPF, the use of somatostatin analogues was shown to
be associated with a higher risk of POPF.69 However, this may be a
reflection of surgeons using somatostatin analogues prophylacti-
cally in higher risk cases. At present, the role of somatostatin ana-
logues remains undefined and requires further study in the context
of high risk cases such as thosewith a soft pancreas and non-dilated
pancreatic duct.
5. Quality standards
PDAC remains an uncommon disease. As mentioned above, the
number of patients who are suitable for treatment with curative
intent is even smaller. As such, most centres and individual sur-
geons do not have extensive experience in this area. Centralisation
has been proposed to overcome some of these challenges as cor-
relation between volume and outcome has been demonstrated for
major pancreatic resections.71,72 However, the relationship be-
tween surgeon and institutional volume and outcome is complex.
Cumulative institutional experience is thought to be most impor-
tant to foster collective knowledge and decrease the likelihood of
failure to rescue.73 However, without formal legislation and due toe management of pancreatic ductal adenocarcinoma, Laparoscopic,
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health services, centralisationmay be impractical or unnecessary in
some settings.74 Moreover, since the volume of patients with PDAC
is ultimately dependent on the size of the population served, some
settings are unlikely to ever have high volume units.74 Thus, it may
be more important to focus on improving the quality of care pro-
vided by improving available infrastructure and committing to
upholding quality standards in PDAC care.75 In a recent study of this
topic, a number of standards have been proposed relating to timely
diagnosis and provision of multidisciplinary care with clearly
defined key performance indicators.75
6. Conclusion
PDAC remains difficult to treat. Over the last generation, peri-
operative outcomes from surgery have improved substantially but
without significant gains in long term survival. The advances in
imaging technology and emergence of EUS have allowed for more
accurate diagnosis and staging. The changes in surgical approach
and a potential paradigm shift in treatment sequencing with
greater use of chemoradiotherapy represent important avenues to
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